The authors examined the effects of zidovudine on neuropsychiatric
measures, at three assessment points separated by 6 months, in 25 HIV-
positive men who took zidovudine for at least 6 months and a comparison
group of 25 HIV-positive men with similar CD4+ T cell counts who had never
taken zidovudine. Zidovudine had no statistically significant effect except
for a slight improvement in Global Assessment of Functioning scale score.
In this small group of subjects there was little benefit but also little
evidence of CNS toxicity from zidovudine.